Trial · NCT03506724

Response to Anti-hypertensives in Pregnant and Postpartum Patients

NCT03506724, Phase 4, Completed, Icahn School of Medicine at Mount Sinai; results first posted 2021-05-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Response to Anti-hypertensives in Pregnant and Postpartum Patients. Trials, record NCT03506724. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03506724

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Response to Anti-hypertensives in Pregnant and Postpartum Patients
NCT number: NCT03506724
Status: Completed
Phases: Phase 4
Enrollment: 109 participants, actual
Lead sponsor: Icahn School of Medicine at Mount Sinai
Conditions: Hypertension in Pregnancy, Preeclampsia
Interventions: Nifedipine, Labetalol
First posted: 2018-04-24
Last updated: 2021-05-24
Results first posted: 2021-05-24
Limitations and caveats: Small sample size and the study was not double blind

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Time to Achieve Non Severe Range Blood Pressure	Ten minute intervals from the time of the first severe range blood pressure, up to 1 hour	Time to achieve goal blood pressure, that is, non severe range blood pressures after medication received.
Primary	Number of Participants to Achieve Non Severe Range Blood Pressure	up to 1 hour	Number of participants by ethnicity to achieve goal blood pressure, that is, non severe range blood pressures after medication received.
Secondary	Frequency of Genetic Variants of Genes	up to 1 year	the frequency of variant alleles in different receptors involved in the response to labetalol and nifedipine administration in the pregnant and postpartum population.
Secondary	Number of Participants With Medication Side Effects	assessed 10 minutes to 1 hour after medication is given	Number of participants with side effect profile to assess the rate of side effects from IV labetalol and oral nifedipine

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Time to Achieve Non Severe Range Blood Pressure	Ten minute intervals from the time of the first severe range blood pressure, up to 1 hour		minutes	MEDIAN
PRIMARY	Number of Participants to Achieve Non Severe Range Blood Pressure	up to 1 hour	participants by ethnicity	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Frequency of Genetic Variants of Genes	up to 1 year	data not collected
SECONDARY	Number of Participants With Medication Side Effects	assessed 10 minutes to 1 hour after medication is given		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Time to Achieve Non Severe Range Blood Pressure	Intravenous Labetalol		10	Inter-Quartile Range 10 to 20	minutes
Time to Achieve Non Severe Range Blood Pressure	Oral Nifedipine		20	Inter-Quartile Range 20 to 30	minutes
Number of Participants to Achieve Non Severe Range Blood Pressure	Intravenous Labetalol	White, Asian, and Hispanic	33		Participants
Number of Participants to Achieve Non Severe Range Blood Pressure	Oral Nifedipine	White, Asian, and Hispanic	31		Participants
Number of Participants to Achieve Non Severe Range Blood Pressure	Intravenous Labetalol	Black	18		Participants
Number of Participants to Achieve Non Severe Range Blood Pressure	Oral Nifedipine	Black	22		Participants
Number of Participants With Medication Side Effects	Intravenous Labetalol	Headache	6		Participants
Number of Participants With Medication Side Effects	Oral Nifedipine	Headache	10		Participants
Number of Participants With Medication Side Effects	Intravenous Labetalol	Nausea	3		Participants
Number of Participants With Medication Side Effects	Oral Nifedipine	Nausea	7		Participants

1 to 10 of 18Source ClinicalTrials.gov

See all 18 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Oral Nifedipine	54
Overall Study	STARTED	Intravenous Labetalol	55
Overall Study	COMPLETED	Oral Nifedipine	54
Overall Study	COMPLETED	Intravenous Labetalol	55
Overall Study	NOT COMPLETED	Oral Nifedipine	0
Overall Study	NOT COMPLETED	Intravenous Labetalol	0

Source ClinicalTrials.gov

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	symptomatic hypotenstion	Pregnancy, puerperium and perinatal conditions	Intravenous Labetalol	0	55
other	symptomatic hypotenstion	Pregnancy, puerperium and perinatal conditions	Oral Nifedipine	1	54

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Intravenous Labetalol	0	55
Total, all-cause mortality	Oral Nifedipine	0	54
Total, other adverse events	Intravenous Labetalol	0	55
Total, other adverse events	Oral Nifedipine	1	54
Total, serious adverse events	Intravenous Labetalol	0	55
Total, serious adverse events	Oral Nifedipine	0	54

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Intravenous Labetalol vs Oral Nifedipine: deaths from any cause	Trial comparisons
Intravenous Labetalol vs Oral Nifedipine: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03506724

GET https://conductscience.org/api/trials/v1/NCT03506724/registered

API reference For AI assistants